A “Letter to Shareholders and Friends” Also Available on January 5
VANCOUVER, Washington, Jan. 03, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that management will hold an investment community conference call on Thursday, January 5, 2017, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical trial and regulatory developments.
Management also announces that it will post a “Letter to Shareholders and Friends” from President and CEO Nader Pourhassan Ph.D. reviewing the Company’s progress and highlighting 2017 milestones to its corporate website at www.cytodyn.com on Thursday, January 5, 2017.
Conference Call and Webcast Instructions
CytoDyn’s management team will host a conference call and live audio webcast on January 5, 2017 at 1:00 p.m. PT / 4:00 p.m. ET.
Interested participants and investors may access this conference call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916 (international).
A live audio webcast may also be accessed via CytoDyn’s corporate web site at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 60 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link: http://cytodyn.equisolvewebcast.com/inv-call-1-5-17.
A replay of the conference call will be available until March 5, 2017. To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international); Conference ID: 13652328.
CONTACTS: Investors: LHA Jody Cain Office: 310-691-7100 E-mail: firstname.lastname@example.org Media: Nader Pourhassan, Ph.D. President & CEO Office: 360-980-8524 Email: email@example.com